Federal contract award
75A50124F33007
CLINICAL STUDIES NETWORK- CLINICAL TRIAL PLANNING & EXECUTION
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | 75A50120D00015 |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $1.8M |
| Current contract value | $1.8M |
| Potential contract value / ceiling | $1.8M |
| Start date | Dec 5, 2023 |
| Current end date | Sep 20, 2026 |
| Potential end date | Sep 20, 2026 |
| Latest award activity | Jul 22, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 22, 2026 | P00005 | $0 | EO 14398. CLINICAL TRIAL PLANNING & EXECUTION FOR SUBLINGUAL ATROPINE BIOEQUIVALENCE BY ROUTE OF ADMINISTRATION STUDY AND CLINICAL TRIAL DATA STORAGE |
| Sep 20, 2025 | P00004 | $24.8K | CLINICAL TRIAL PLANNING & EXECUTION FOR SUBLINGUAL ATROPINE BIOEQUIVALENCE BY ROUTE OF ADMINISTRATION STUDY AND CLINICAL TRIAL DATA STORAGE |
| Sep 10, 2025 | P00003 | $-24.8K | CLINICAL TRIAL PLANNING & EXECUTION FOR SUBLINGUAL ATROPINE BIOEQUIVALENCE BY ROUTE OF ADMINISTRATION STUDY |
| Mar 7, 2025 | P00002 | $0 | STATISTICAL DATA COORDINATING CENTER - SUBLINGUAL ATROPINE BIOEQUIVALENCE BY ROUTE OF ADMINISTRATION |
| May 6, 2024 | P00001 | $0 | CLINICAL STUDIES NETWORK- CLINICAL TRIAL PLANNING & EXECUTION |
| Dec 5, 2023 | 0 | $1.8M | CLINICAL STUDIES NETWORK- CLINICAL TRIAL PLANNING & EXECUTION |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.